California-based biopharmaceutical company Exelixis is the 17th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

News Alert

Exelixis, Maker of Expensive Cancer Drugs, Is Latest Manufacturer to Impose 340B Contract Pharmacy Conditions

Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report